Artios Pharma Limited (Cambridge, UK), a leading DNA Damage Response company developing innovative treatments for cancer, announced the completion of a $84 million financing following high interest from investors.
Artios is actively developing a pipeline of highly promising first-in-class DNA Damage Response (DDR) therapies identified from a global network of leading researchers in the DDR field, including through Cancer Research UK. The inhibition of novel DNA repair targets like Polθ, in tumours where DNA damage response factors have been lost or down regulated, will lead to cancer cells being selectively killed without harming normal cells. This creates an opportunity for such products to be used both in monotherapy and in combination with existing and future cancer therapies.
The company’s investors include Pfizer Ventures, Novartis Venture Fund, SV Life Sciences, Merck Ventures, Imperial Innovations, Arix Bioscience PLC, CRT Pioneer Fund, and AbbVie Ventures.
Artios Pharma, founded by SV Health Investors in 2016, is led by an experienced scientific and leadership team with proven expertise in DDR drug discovery. The company is building a pipeline of next-generation DDR programmes to target hard to treat cancers.